Drugs / Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06353152 | Nov 2023 → Nov 2025 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06353152 ↗ |